Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Roche Launches First Sugar-Transferase for New Glyco-Engineering Portfolio

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Enzyme supports applications from research to Biopharmaceutical Manufacturing.

Roche announced the launch of its new alpha-2,6-Sialyltransferase for in vitro sialylation of glycoproteins and complex molecules as human monoclonal antibodies (mAbs). The enzyme, which is offered for research and pilot scale applications, is produced under animal-origin free conditions and offers a very high lot-to-lot consistency.

“This launch is the first in a series to offer a complete glyco-engineering portfolio of key enzymes and activated sugars covering a broad spectrum of applications,” said Ruedi Stoffel, Head of Biochemical Reagents & Custom Biotech. “The initial feedback from bio-manufacturing customers showed that our continuous scientific and technical support throughout the up-scaling and development process differentiates Roche as a strong partner.”

The alpha-2,6-Sialyltransferase delivers up to 95% bi-antennary sialylation of N-Glycan chains within 6 – 8 hours, a performance which is currently not offered by competitor products. It is based on a human genome sequence and expressed in mammalian expression systems. Over the coming months, Roche plans to complete the portfolio through launches of additional Sialyl-and Galactosyltransferases.

Glycosylation is considered to be one of the main sources of biologics’ heterogeneity and is seen as a critical quality attribute by regulatory bodies. The implementation of Quality by Design Standards in the manufacturing of Active Pharmaceutical Ingredients such as mAbs with specific glycosylation patterns is expected to play a central role in future bio-manufacturing processes.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

US FDA Grants Therapy Designation for Roche’s Investigational Medicine ACE910
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of haemophilia A.
Tuesday, September 08, 2015
Roche's Investigational Immunotherapy Shrank Bladder Cancer Tumors in Pivotal Study
The company have announced the success of atezolizumab in shrinking tumors people with locally advanced or metastatic urothelial bladder cancer.
Tuesday, July 14, 2015
Roche to Acquire Santaris Pharma
Acquisition to expand Roche's discovery and development of RNA-targeting medicines.
Tuesday, August 05, 2014
Roche and Molecular Partners Enter into Alliance
Partnership will combine novel biologics with Roche drug-conjugate technology to develop new cancer treatments.
Wednesday, December 04, 2013
Roche’s MycoTOOL Receives Acceptance from Canadian Authorities
PCR test reduces time for mycoplasma detection from one month to one day.
Friday, June 14, 2013
Scientific News
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Researchers Discover A New Mechanism of Proteins to Block HIV
Certain IFITM proteins block and inhibit cell-to-cell transmission of HIV.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos